0001562180-18-004642.txt : 20181121 0001562180-18-004642.hdr.sgml : 20181121 20181121162132 ACCESSION NUMBER: 0001562180-18-004642 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181119 FILED AS OF DATE: 20181121 DATE AS OF CHANGE: 20181121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yoo Stephen CENTRAL INDEX KEY: 0001652825 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 181198433 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC, STREET 2: 9600 BLACKWELL ROAD, SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-11-19 false 0001590877 REGENXBIO Inc. RGNX 0001652825 Yoo Stephen C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210 ROCKVILLE MD 20850 false true false false Chief Medical Officer Common Stock 2018-11-19 4 M false 20414.00 0.85 A 20414.00 D Common Stock 2018-11-19 4 S false 2761.00 57.08 D 17653.00 D Common Stock 2018-11-19 4 S false 2300.00 58.37 D 15353.00 D Common Stock 2018-11-19 4 S false 9092.00 59.61 D 6261.00 D Common Stock 2018-11-19 4 S false 4361.00 60.25 D 1900.00 D Common Stock 2018-11-19 4 S false 800.00 61.55 D 1100.00 D Common Stock 2018-11-19 4 S false 1100.00 63.21 D 0.00 D Employee Stock Option (Right to Buy) 0.85 2018-11-19 4 M false 20414.00 0.00 D 2024-11-03 Common Stock 20414.00 61244.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $56.79 to $57.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $57.90 to $58.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $58.91 to $59.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $59.93 to $60.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $61.02 to $61.845. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $62.80 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2018-11-21